Management of resistant prolactinomas

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 10, 2006, Pages 552-561

  Olafsdottir, Agusta ^a   Schlechte, Janet ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Bromocriptine; Cabergoline; Dopamine agonist resistance; Macroadenoma; Pituitary tumor

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; MESSENGER RNA; PERGOLIDE; PROLACTIN; QUINAGOLIDE;

ABDOMINAL PAIN; ANXIETY DISORDER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CLINICAL TRIAL; CONSTIPATION; CONSTRICTIVE PERICARDITIS; DEPRESSION; DIZZINESS; DROWSINESS; DRUG HYPERSENSITIVITY; DYSKINESIA; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; HYPOPHYSIS ADENOMA; HYPOTENSION; INSOMNIA; LEG CRAMP; LUNG FIBROSIS; MASTALGIA; MICROADENOMA; NAUSEA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PLEURAL FIBROSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PSYCHOSIS; RAYNAUD PHENOMENON; REVIEW; THROMBOEMBOLISM; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TUMOR VOLUME; VALVULAR HEART DISEASE; VOMITING;

DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; HUMANS; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 33749563821     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0290     Document Type: Review

References (79)

1. Jane JA and Laws ER (2001) The surgical management of pituitary adenomas in a series of 3093 patients. J Am Coll Surg 193: 651-659
2. Nomikos P et al. (2001) Current management of prolactinomas. J Neuroophthalmol 54:139-150
3. Kovacs K et al. (1995) Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. J Neurosurg 82: 886-890
4. Delgrange E et al. (1996) Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 134: 454-456
5. Pellegrini I et al. (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69: 500-509
6. Brue T et al. (1992) Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 74: 577-584
7. Ho KY and Thorner MO (1988) Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 36: 67-82
8. Grossman A et al. (1980) Two new dopamine agonists that are long acting in vivo but short acting in vitro. Clin Endocrinol (Oxf) 13: 595-599
9. Rasmussen C et al. (1987) CV 205-602: A new longacting drug for inhibition of prolactin hypersecretion. Clin Endocrinol (Oxf) 26: 321-326
10. Rains CP et al. (1995) Cabergoline. A review of its pharmacological properties and therapeutic potential in treatment of hyperprolactinaemia and inhibition of lactation. Drugs 49: 255-279
11. De Camilli P et al. (1979) Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 278: 252-254
12. Liu YF et al. (1994) G protein specificity in receptor-effector coupling. Analysis of the roles of G0 and Gi2 in GH4C1 pituitary cells. J Biol Chem 269: 13880-13886
13. Maurer RA (1981) Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 294: 94-97
14. Kolesnick RN and Gershengorn MC (1986) Thyrotropin-releasing hormone stimulation of prolactin secretion is coordinately but not synergistically regulated by an elevation of cytoplasmic calcium and 1,2-diacylglycerol. Endocrinology 119: 2461-2466
15. 2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem 263: 10127-10134
16. Tindall GT et al. (1982) Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55: 1178-1183
17. Duffy AE et al. (1988) Effect of bromocriptine on secretion and morphology of human prolactin cell adenomas in vitro. Horm Res 30: 32-38
18. Thorner MO et al. (1980) A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J Endocrinol Metab 50: 1026-1033
19. Verhelst J et al. (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84: 2518-2522
20. Molitch ME et al. (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60: 698-705
21. Colao A et al. (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89: 1704-1711
22. Ferrari CI et al. (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 46: 409-413
23. Di Sarno A et al. (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86: 5256-5261
24. Webster J et al. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331: 904-909
25. McElvaney NG et al. (1988) Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 148: 2231-2236
26. Turner TH et al. (1984) Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J (Clin Res Ed) 289: 1101-1103
27. Sabuncu T et al. (2001) Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med 40: 857-861
28. Badano AR et al. (1979) Bromocriptine in the treatment of hyperprolactinemic amenorrhea. Fertil Steril 31: 124-129
29. Moro M et al. (1991) Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study. Horm Res 35: 137-141
30. Crosignani PG et al. (1982) Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride. Fertil Steril 37: 61-67
31. Bergh T et al. (1978) Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol (Copenh) 88: 435-451
32. Thorner MO and Besser GM (1978) Bromocriptine treatment of hyperprolactinaemic hypogonadism. Acta Endocrinol Suppl (Copenh) 216: 131-146
33. Wang C et al. (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol (Oxf) 27: 363-371
34. Moriondo P et al. (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60: 764-772
35. Cannavo S et al. (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22: 354-359
36. Colao A et al. (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148: 325-331
37. De Rosa M et al. (2004) Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 89: 621-625
38. Ferrari C et al. (1989) Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 68: 1201-1206
39. Wass JA et al. (1982) Bromocriptine in management of large pituitary tumours. Br Med J (Clin Res Ed) 284: 1908-1911
40. Liuzzi A et al. (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313: 656-659
41. Pinzone JJ et al. (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85: 3053-3057
42. Sieck JO et al. (1986) Extrasellar prolactinomas: successful management of 24 patients using bromocriptine. Horm Res 23: 67-76
43. van't Verlaat JW et al. (1986) Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study. Acta Endocrinol (Copenh) 112: 487-493
44. Colao A et al. (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85: 2247-2252
45. Pontikides N et al. (2000) Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas. Pituitary 2: 277-281
46. Ferrari C et al. (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 126: 489-494
47. Horowitz BL et al. (1983) Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin. Am J Neuroradiol 4: 415-417
48. Freda PU et al. (2000) Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 85: 8-13
49. Orrego JJ et al. (2000) Pergolide as primary therapy for macroprolactinomas. Pituitary 3: 251-256
50. Kleinberg DL et al. (1983) Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 309: 704-709
51. Hermite ML et al. (1983) Treatment of hyperprolactinemic patients with pergolide. Acta Endocrinol 103: 441-445
52. Di Sarno A et al. (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53: 53-60
53. Caccavelli L et al. (1994) Decreased expression of the two D2 dopamine receptor isoforms in bromocriptineresistant prolactinomas. Neuroendocrinology 60: 314-322
54. Delgrange E et al. (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 147: 751-758
55. Brue T et al. (1992) Prolactinomas and resistance to dopamine agonists. Horm Res 38: 84-89
56. Krupp P and Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65: 823-827
57. Musatti RE et al. (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10: 333-337
58. Ricci E et al. (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16: 791-793
59. Howell D et al. (2005) The use of high-dose cabergoline in an adolescent patient with macroprolactinoma. J Pediatr Hematol Oncol 27: 326-329
60. Gillam M et al. (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87: 4447-4451
61. Morange I et al. (1996) Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 135: 413-420
62. Rohmer V et al. (2000) Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. Ann Endocrinol (Paris) 61: 411-417
63. Colao A et al. (1997) Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82: 876-883
64. Hamilton DK et al. (2005) Surgical outcomes in hyporesponsive prolactinomas: Analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8: 53-60
65. Landolt AM et al. (1982) Bromocriptine: does it jeopardize the result of later surgery for prolactinomas? Lancet 2 (8299): 657-658
66. Faglia G et al. (1983) Influence of previous bromocriptine therapy on surgery for microprolactinomas. Lancet 1(8316): 133-134
67. Thomson JA et al. (1994) Ten year follow-up of microprolactinoma treated by trans-sphenoidal surgery. BMJ 309: 409-410
68. Becker G et al. (2002) Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol 178: 173-186
69. Gittoes NJL (2005) Pituitary radiotherapy: current controversies. Trends Endocrinol Metab 16: 407-413
70. Laws ER et al. (2004) Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol 69: 257-272
71. Pan L et al. (1998) Pituitary adenomas: the effect of gamma knife radiosurgery on tumor growth and endocrinopathies. Stereotact Funct Neurosurg 70 (Suppl 1): 119-126
72. Brada M et al. (2004) Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxf) 61: 531-543
73. Sheehan JP et al. (2005) Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy and role in the neurosurgical treatment armamentarium. J Neurosurg 102: 678-691
74. Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312: 1365-1370
75. Brodsky JB et al. (1980) Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 138: 1165-1167
76. Testa G et al. (1998) Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58: 69-73
77. Corenblum B and Donovan L (1993) The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 59: 671-673
78. Schlechte J et al. (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64: 1021-1026
79. Klibanski A and Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315: 542-546